Wound care, into the centers and practices where chronic wounds get treated.
Wound care is a portfolio category. Most practices treating chronic wounds carry product lines from four or five manufacturers. Solara consolidates the call — one rep, one quarterly review, one accountable relationship — and the practice stops resenting the parade.
Why wound-care manufacturers need a portfolio rep
Practices treating chronic wounds — diabetic ulcers, venous stasis, pressure injuries — have a fixed amount of attention for vendor visits. They can absorb one rep covering five products, not five reps covering one product each. The vendor that consolidates wins more time, more trial, more standing reorder volume.
What changes when wound care runs on the Solara network.
Portfolio reps, not single-product reps
Reps carry non-competing wound-care lines across complementary call points: dressings, skin substitutes, NPWT, debridement, and adjunct therapies. Practices get one accountable contact for the category.
LCD and reimbursement literacy
Reps work fluently with skin-substitute LCDs, application/billing requirements, and clawback risk. Practices avoid the documentation pitfalls that turn a billed treatment into a denial six months later.
Wound-center and home-health coverage
Reps cover hospital-based wound centers, freestanding wound clinics, podiatry and vascular practices, primary care, and home-health agencies — the full patient journey for a chronic wound.
Specialties served by this category.
- ·Wound-care specialists
- ·Podiatry
- ·Vascular surgery
- ·Plastic and reconstructive surgery
- ·Primary care (chronic-wound subset)
- ·Endocrinology (diabetic-foot subset)
Who Solara distributes for in this category.
- ·Skin substitutes / cellular and tissue-based products
- ·Advanced dressings (foam, alginate, collagen, antimicrobial)
- ·Negative-pressure wound therapy (traditional and disposable)
- ·Debridement systems (ultrasonic, hydrosurgical, enzymatic)
- ·PENS / neuromodulation devices for diabetic neuropathy
- ·Diagnostic devices (ABI/TBI, perfusion imaging)
What manufacturers ask before they pilot.
- What wound-care product categories does Solara cover?
- Skin substitutes (cellular and tissue-based products), advanced dressings, negative-pressure wound therapy, debridement systems, neuromodulation/PENS devices for diabetic neuropathy, and adjacent diagnostic devices like ABI/TBI and perfusion imaging.
- How does Solara handle skin-substitute LCDs and clawback risk?
- Reps are trained on current LCD requirements (application limits, documentation, medical-necessity criteria) for the products they carry. The platform makes those requirements visible at the point of sale so practices avoid denial-prone application patterns.
- Can Solara reps cover home-health agencies and DME suppliers?
- Yes — wound-care territories are designed to cover the full patient journey, including hospital wound centers, freestanding wound clinics, specialty practices, primary care, home-health agencies, and DME suppliers handling wound supplies.
- Does Solara distribute the NS100 PENS device?
- Solara reps are the field force for NS100-class PENS devices indicated for painful diabetic neuropathy. Distribution is in-office (physician-administered) with reimbursement under PENS-specific CPT codes; Solara handles physician training, reimbursement support, and adoption analytics.
- How does Solara coordinate with manufacturer's quality and regulatory teams?
- Adverse-event reports, product complaints, and post-market signals are logged through the platform and routed to manufacturer quality. Manufacturer-of-record responsibilities (MDR/MedWatch reporting, recall handling) remain with the manufacturer; Solara provides the field-side data feed.
Pilot a wound care territory in 30 days.
Book a working session — we’ll load your target sub-segment into Solara live, walk through territory coverage, and propose a pilot scope.